Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Rawlins

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Clinical Pharmacology and Therapeutics|June 29, 2012
LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trialB Zambrowicz, J Freiman, P M Brown, et al.
ACS Medicinal Chemistry Letters|June 18, 2025
Discovery of Pyrimidoindolones as Novel Family VIII Bromodomain BindersJeffrey A Boerth, Marianne Schimpl, Simon C C Lucas, et al.
Journal of Medicinal Chemistry|September 30, 2009
Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetesNicole C Goodwin, Ross Mabon, Bryce A Harrison, et al.
Bioorganic & Medicinal Chemistry Letters|March 8, 2021
Free energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferaseDaniel H O' Donovan, Clare Gregson, Martin J Packer, et al.
Journal of Medicinal Chemistry|January 4, 2017
Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment of DiabetesNicole C Goodwin, Zhi-Ming Ding, Bryce A Harrison, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 27, 2017
LX2761, a Sodium/Glucose Cotransporter 1 Inhibitor Restricted to the Intestine, Improves Glycemic Control in MiceDavid R Powell, Melinda G Smith, Deon D Doree, et al.
ACS Medicinal Chemistry Letters|January 16, 2015
Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of GlaucomaBryce A Harrison, Zheng Y Almstead, Hugh Burgoon, et al.
Journal of Medicinal Chemistry|November 22, 2021
Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 MethyltransferaseSharan K Bagal, Clare Gregson, Daniel H O' Donovan, et al.
Journal of Medicinal Chemistry|March 8, 2021
Generating Selective Leads for Mer Kinase Inhibitors-Example of a Comprehensive Lead-Generation StrategyJ Willem M Nissink, Sana Bazzaz, Carolyn Blackett, et al.
Journal of Medicinal Chemistry|October 17, 2009
Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucomaBryce A Harrison, N Andrew Whitlock, Michael V Voronkov, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Clinical Pharmacology and Therapeutics|June 29, 2012
LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trialB Zambrowicz, J Freiman, P M Brown, et al.
ACS Medicinal Chemistry Letters|June 18, 2025
Discovery of Pyrimidoindolones as Novel Family VIII Bromodomain BindersJeffrey A Boerth, Marianne Schimpl, Simon C C Lucas, et al.
Journal of Medicinal Chemistry|September 30, 2009
Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetesNicole C Goodwin, Ross Mabon, Bryce A Harrison, et al.
Bioorganic & Medicinal Chemistry Letters|March 8, 2021
Free energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferaseDaniel H O' Donovan, Clare Gregson, Martin J Packer, et al.
Journal of Medicinal Chemistry|January 4, 2017
Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment of DiabetesNicole C Goodwin, Zhi-Ming Ding, Bryce A Harrison, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 27, 2017
LX2761, a Sodium/Glucose Cotransporter 1 Inhibitor Restricted to the Intestine, Improves Glycemic Control in MiceDavid R Powell, Melinda G Smith, Deon D Doree, et al.
ACS Medicinal Chemistry Letters|January 16, 2015
Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of GlaucomaBryce A Harrison, Zheng Y Almstead, Hugh Burgoon, et al.
Journal of Medicinal Chemistry|November 22, 2021
Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 MethyltransferaseSharan K Bagal, Clare Gregson, Daniel H O' Donovan, et al.
Journal of Medicinal Chemistry|March 8, 2021
Generating Selective Leads for Mer Kinase Inhibitors-Example of a Comprehensive Lead-Generation StrategyJ Willem M Nissink, Sana Bazzaz, Carolyn Blackett, et al.
Journal of Medicinal Chemistry|October 17, 2009
Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucomaBryce A Harrison, N Andrew Whitlock, Michael V Voronkov, et al.
Pageof 5